04 July 2022 | Monday | News
StimLabs is expanding their product portfolio to address the widening range of needs in healthcare facilities. The introduction of Enverse is part of StimLabs' aim to simplify patient care for both physicians and the hospital systems in which they practice. Both physician owned and hospital owned facilities now have StimLabs' solutions at their disposal.
Enverse is a translucent dehydrated complete human placental membrane (dCHPM) allograft designed for use as a wound covering over acute and chronic wounds. The dCHPM allograft is processed to retain the intermediate layer using the patented Clearify™ method. This allograft is stabilized using a patented oven-dehydration process, resulting in a compact, translucent format. Enverse allows for increased application site visibility while maintaining excellent handling characteristics.1
StimLabs' differentiated placental membrane-based product portfolio remains of the highest quality with each product processed using StimLabs' patented Clearify process. StimLabs takes a scientific approach to process development, encompassing the identification, optimization, and retention of native structures and structural components found in birth tissue. With the ultimate goal of preserving all the potential that birth tissue offers, StimLabs continues to innovate the tissue space and deliver market-leading products.
Most Read
Bio Jobs
News